AMGN Maintained by Guggenheim -- Price Target Lowered to $378

gurufocus.com · 2026-10-13

Amgen (AMGN) Analyst Rating Update On October 12, 2026, the current rating for Amgen (AMGN) remains Neutral according to Guggenheim. The price target has bee

TickrTrends take: Guggenheim's price target reduction to $378 aligns with TickrTrends' assessment that AMGN is currently overvalued, suggesting analyst sentiment may be converging with valuation metrics that indicate limited upside at present levels. For investors focused on valuation, this downward target adjustment reinforces the importance of monitoring whether the stock's current trading range continues to command a premium relative to fundamental metrics in the Healthcare sector. The maintained rating coupled with the lowered price target reflects a nuanced view where the company's business may remain sound, but its valuation warrants caution.

Read the full story at gurufocus.com →